Login to Your Account

FDA Panel Rejects Jazz Fibromyalgia Drug

By Donna Young

Monday, August 23, 2010
BETHESDA, Md. – An FDA advisory panel Friday said it would be too risky to permit Jazz Pharmaceuticals Inc. to market its oral liquid sodium oxybate drug under two names in two different concentrations for separate indications due to the risk of dual prescribing leading to overdose, in addition to the medicine's already known potential for misuse and abuse. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription